



INDOCO REMEDIES LTD

## indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) • Website : [www.indoco.com](http://www.indoco.com)  
PHONES : (91-22) 3386 1000 / 3386 1250 • FAX : (91-22) 2652 3067 / 2652 3976 • CIN : L85190MH1947PLC005913

March 31, 2017

|  |   |
|--|---|
| To<br>The Listing Department<br><b>National Stock Exchange of India<br/>Limited</b><br>Exchange Plaza,<br>Bandra - Kurla Complex<br>Bandra (East)<br><u>Mumbai - 400 051</u> | To<br>The Listing Department<br><b>Bombay Stock Exchange Limited</b><br>Floor 25, P. J. Towers,<br>Dalal Street,<br><u>Mumbai - 400 001</u> |
|--|---|

Dear Sir,

### Sub : Disclosures under Regulation 30

The USFDA had inspected our drug manufacturing facility (Plant II & Plant III, L-32,33,34 Verna Industrial Estate Area, Verna, Goa) , from August 31<sup>st</sup> 2016 to September 4<sup>th</sup> , 2016. As an outcome of this inspection, the facility received 6 observations in Form 483, which do not pertain to data integrity. Based on the review of compliance response, FDA accepted our response to 4 observations. However, FDA remains concerned with respect to 2 observations, pertaining to one specific product, for which we are contract manufacturer, for one of our customers and consequently we have received a warning letter from USFDA dated 27<sup>th</sup> March 2017, today.

We as a company are fully committed in resolving the issue and will respond at the earliest. The company is also committed to its philosophy of highest quality in manufacturing, operations, systems integrity and cGMP culture.

We continue to supply products from the above mentioned facility to meet our obligations to our customers and the patients in the United States of America.

Thanking you,

Yours faithfully,  
For Indoco Remedies Limited

Sunil D. Joshi  
Company Secretary